ArticleWorld journal of surgical oncology2025
Metabolic syndrome as a prognostic factor in advanced pancreatic cancer: a predictive model and chemotherapy evaluation.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Syndrome and Pancreatic Cancer: Linking Insulin Resistance, Inflammation, and Carcinogenesis.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aimed to identify independent prognostic factors for advanced unresectable pancreatic ductal adenocarcinoma (PDAC) and construct a nomogram-based prediction model. The efficacy of different chemotherapy regimens was evaluated based on metabolic risk levels.
methodsClinical data from 276 patients with unresectable PDAC treated between 2020 and 2022 were retrospectively analyzed. Cox proportional hazards regression identified prognostic factors, and survival analysis was performed using Kaplan-Meier methods. A nomogram was developed, and ROC analysis assessed its predictive performance. Two-way ANOVA evaluated chemotherapy efficacy, and TCGA transcriptomic data explored metabolic correlations.
resultsMetabolic syndrome (MetS) and distant metastasis were independent prognostic factors. Patients with MetS had significantly shorter survival. The nomogram showed good discrimination (AUC: 0.815 training, 0.793 validation). Patients without MetS had better outcomes with FOLFIRINOX or GS regimens. Transcriptomic analysis revealed metabolic pathways linked to PDAC progression.
conclusionsMetS and distant metastasis significantly impact PDAC prognosis. Patients without MetS benefit more from specific chemotherapy regimens. Our predictive model may aid personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.